A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Active, not recruiting · Phase 2, Phase 3 · NCT06109272
Conditions: Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $533,788
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 89
About the trial
- Sponsor
- AbbVie
- Tested
- Livmoniplimab (drug), Budigalimab (drug), Durvalumab (drug), Atezolizumab (drug), Bevacizumab (drug), Tremelimumab (drug)
- Dates
- Started 2024-01-11; completion 2027-01
- Results posted
- Not yet
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. In Stage 1, there are 3 treatment arms and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), atezo…
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $533,788 in research payments for this study in 2025 (54 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Farshid Dayyani, M.D., PH.D. Medical Oncology · Orange, CA
- Daneng Li, M.D. Medical Oncology · Duarte, CA
- Joseph W. Franses, MD Medical Oncology · Chicago, IL
- Michael F. Driscoll, M.D. Medical Oncology · Louisville, KY
- Reena Salgia, M.D. Gastroenterology · Detroit, MI
- Yan Ji, M.D, PH.D. Hematology & Oncology · Saint Paul, MN
- Benjamin R. Tan, MD Medical Oncology · Saint Louis, MO
- Rafael D. Betancourt Garcia, MD Hematology & Oncology · Guaynabo, PR
- David Hsieh, M.D. Medical Oncology · Dallas, TX
- Lucas Wong, M.D. Hematology & Oncology · Temple, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $249,634
- Uci Health-Orange, CA $116,788
- The University of Texas $55,329
- The University of Chicago $28,288
- Washington Univ Sch of Med $26,863
- Puerto Rico Medical Research Center $24,866
- Henry Ford Health Hospital, MI $12,000
- Baylor Research Institute $9,754
- Norton Healthcare Inc $5,741
- Health PArtners Institute $2,400
- $2,125
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.